← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2007First marketed drug
Feb 18, 2014First NDA
Feb 18, 2014Last known activity
Nov 1, 2013
Acquired by Lundbeck on Jun 23, 2014
Timeline
Drugs by trial phase (7 distinct, 17 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Arthritis
- Arthritis, Rheumatoid
- Atrophy
- Attention Deficit Disorder with Hyperactivity
- Autonomic Nervous System Diseases
- Disease
- Fatigue
- Fatigue Syndrome, Chronic
- Fibromyalgia
- Gait Disorders, Neurologic
- Hyperkinesis
- Hypotension
- Hypotension, Orthostatic
- Kidney Diseases
- Kidney Failure, Chronic
- Multiple System Atrophy
- Myofascial Pain Syndromes
- Nervous System Diseases
- Parkinson Disease
- Pure Autonomic Failure
- Shy-Drager Syndrome
- Spinal Cord Injuries
- Syndrome
Marketed drugs (1)
Recent trials (20)
- NCT01927055Lead sponsorPhase 3Nov 1, 2013
- NCT01468259Study directorPhase 1Oct 1, 2012
- NCT01468259Lead sponsorPhase 1Oct 1, 2012
- NCT01331122Lead sponsorPhase 1/Phase 2Apr 1, 2012
- NCT01354158CollaboratorPhase 1May 1, 2011
- NCT01327066Lead sponsorPhase 1Mar 1, 2011
- NCT01116141Lead sponsorPhase 2Sep 1, 2010
- NCT00977171Lead sponsorPhase 2Jul 1, 2010
- NCT01149629Lead sponsorPhase 1Jul 1, 2010
- NCT01176240Lead sponsorPhase 3Jun 1, 2010
- NCT01176240Study directorPhase 3Jun 1, 2010
- NCT01176240Study chairPhase 3Jun 1, 2010
- NCT00983814Lead sponsorPhase 2Oct 1, 2009
- NCT01132326Lead sponsorPhase 3Jan 1, 2009
- NCT01323374Lead sponsorPhase 2Jan 1, 2009
Details
- Founded
- Charlotte, NC, US Jan 1, 2004
- First NDA
- Feb 18, 2014
- Last known activity
- Nov 1, 2013
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval
Notes
Acquired by Lundbeck 19 Dec 2014